{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:50Z","timestamp":1791357110726,"version":"4.3.1"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T00:00:00Z","timestamp":1255392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>Cormac I, Brown A, Creasey S, Ferriter M, Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine.<\/jats:p><jats:p><jats:bold>Objective:\u2002<\/jats:bold> To investigate the effect of a complete smoking ban on a group of psychiatric inpatients maintained on the antipsychotic medication clozapine.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> Retrospective data on clozapine dose and plasma levels were collected from a three month period before and a six month period after the introduction of the smoking ban.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Before the ban only 4.2% of patients who smoked had a plasma clozapine level \u22651000\u2003\u03bcg\/l but after the ban this increased to 41.7% of the sample within the six month period following the ban despite dose reductions.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Abrupt cessation of smoking is associated with a potentially serious risk of toxicity in patients taking clozapine. Plasma clozapine levels must be monitored closely and adjustments made in dosage, if necessary, for at least six months after cessation.<\/jats:p>","DOI":"10.1111\/j.1600-0447.2009.01482.x","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T15:24:18Z","timestamp":1255447458000},"page":"393-397","source":"Crossref","is-referenced-by-count":43,"title":["A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine"],"prefix":"10.1111","volume":"121","author":[{"given":"I.","family":"Cormac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Creasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ferriter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Huckstep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38944.382106.BE"},{"key":"e_1_2_10_3_2","unstructured":"National Institute for Health and Clinical Excellence.Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Clinical Practice Guideline Number 82. 2009. Available at:http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG82FullGuideline.pdf(accessed 21 September 2009)."},{"key":"e_1_2_10_4_2","volume-title":"The south London and Maudsley NHS foundation trust and Oxleas foundation trust prescribing guidelines","author":"Taylor D","year":"2007"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200303000-00006"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000164609.14808.93"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000146622.59764.dd"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199910000-00016"},{"key":"e_1_2_10_9_2","first-page":"491","article-title":"Atypical antipsychotic dosing: the effect of smoking and caffeine","volume":"55","author":"De Leon J","year":"2004","journal-title":"Psychopharmacology"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200112000-00005"},{"key":"e_1_2_10_11_2","volume-title":"The south London and Maudsley NHS foundation trust and Oxleas foundation trust prescribing guidelines","author":"Taylor D","year":"2005"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1192\/pb.29.1.18"},{"key":"e_1_2_10_13_2","volume-title":"British national formulary","author":"Joint Formulary Committee","year":"2006"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0506"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106221.36344.4d"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.2009.01482.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.2009.01482.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:50:15Z","timestamp":1697428215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.2009.01482.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1600-0447.2009.01482.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01482.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}